Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-05-25

Clinical Trial Update: SGI-110 in Combination With Carboplatin in Ovarian Cancer [Phase 2]

View source ↗

Summary

Results from a Phase 2 trial of SGI-110 (guadecitabine) plus carboplatin in ovarian cancer have been completed and posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • CARBOPLATIN (Carboplatin)
  • SGI-110 (guadecitabine)

Snippet

Sponsor: Astex Pharmaceuticals, Inc. | Conditions: Ovarian Cancer | Phase 2 | Status: COMPLETED | Results posted: 2021-05-25